A Multi-National, Randomized, Phase III, GCIG [Gynecologic Cancer Intergroup] Intergroup Study Comparing Pegylated Liposomal Doxorubicin [doxorubicin liposomal] and Carboplatin Versus Paclitaxel and Carboplatin in Patients With Platinum-Sensitive Epithelial Ovarian Cancer in Late Relapse (greater than 6 Months).

Trial Profile

A Multi-National, Randomized, Phase III, GCIG [Gynecologic Cancer Intergroup] Intergroup Study Comparing Pegylated Liposomal Doxorubicin [doxorubicin liposomal] and Carboplatin Versus Paclitaxel and Carboplatin in Patients With Platinum-Sensitive Epithelial Ovarian Cancer in Late Relapse (greater than 6 Months).

Completed
Phase of Trial: Phase III

Latest Information Update: 24 May 2017

At a glance

  • Drugs Doxorubicin liposomal (Primary) ; Carboplatin; Paclitaxel
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Acronyms CALYPSO
  • Most Recent Events

    • 24 May 2017 Results comparing Trabectedin-Based Versus Platinum-Based Treatment in Relapsed, Partially Platinum Sensitive Ovarian Cancer patients from two randomised trials (OVA-301 and CALYPSO) presented at the 22nd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
    • 13 Jan 2014 Status changed from active, no longer recruiting to completed as reported in ClinicalTrials.gov record.
    • 03 Nov 2012 Planned number of patients changed from 864 to 974.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top